THC + CBD and Memory Study
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-40
SponsorHartford Hospital
About this trial
Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.
Eligibility criteria
Qualifiers
Right-handed
Prior MJ users (has used MJ at least once in the past year, but no more than 1x/month in the past 12 months)
Medically healthy (as determined by medical history and treatment)
Adequate comprehension of English in order to complete study materials
Disqualifiers
Participant currently uses psychoactive medications or substances
Psychiatric diagnoses (determined by DSM-V)
Participant heavily or regularly uses MJ (more than 1x/month in the past year)
Current or past substance dependence (including MJ)
Trial design
Treatments tested in this trial
- High THC/No CBD Marihuana
- High THC/High CBD Marihuana
- No THC/No CBD Marihuana
Treatment groups
9 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Hartford Hospital
Lead sponsor
Yale University
Collaborator
Source ClinicalTrials.gov